PMV Pharmaceuticals, Inc. PMVP

PMVP Company Overview

PMV Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision oncology therapies targeting p53 mutations in cancer. The company operates within the biotechnology and oncology therapeutics industries, with its research centered on developing small molecule drugs designed to reactivate mutant p53 proteins, which are among the most commonly altered tumor suppressor genes in human cancers. PMV’s primary product candidate is rezatapopt (PC14586), an investigational therapy designed to selectively target cancers harboring the TP53 Y220C mutation. The company primarily serves oncology patients and healthcare systems through clinical-stage drug development activities and collaborations with research institutions and clinical investigators.

PMV Pharmaceuticals was founded in 2013 based on scientific research conducted at Princeton University involving p53 biology and structure-guided drug discovery. The company evolved from an early-stage research platform into a publicly traded biotechnology company focused on precision medicine for genetically defined cancers. Its strategic positioning is tied to its proprietary understanding of mutant p53 protein conformations and its ability to develop mutation-specific therapeutics in an area historically considered difficult to drug within oncology research.